Long COVID: U.S. government to test Pfizer's Paxlovid for helping patients

U.S. government to test Pfizer's Paxlovid for long COVID The U.S. National Institutes of Health's $1 billion RECOVER Initiative has picked Pfizer Inc's antiviral drug Paxlovid as the first treatment it will study in patients with long COVID, organizers of the study said on Thursday. Julie Steenhuysen Reuters

...

The trial will investigate a leading theory of the cause of long COVID, which holds that fragments of the virus persist in the tissues of some individuals, causing prolonged symptoms.

...